C-type lectin domain family 14 member A (CLEC14A)

C-type lectin domain family 14 member A (CLEC14A) is a type I transmembrane protein predominantly expressed in endothelial cells, especially in tumor vasculature[1][2][3][5]. It possesses a C-type lectin domain, an EGF-like domain, and a sushi-like domain in its extracellular region[3]. CLEC14A regulates angiogenesis and lymphangiogenesis by interacting with vascular endothelial growth factor receptor 3 (VEGFR-3) and modulating VEGFR-2 signaling[1][3]. Its functions include controlling endothelial cell-cell adhesion, migration, tube formation, and maintaining vascular integrity[1][2][5]. CLEC14A is overexpressed in tumor blood vessels, making it a marker of tumor endothelial cells[1][2][3]. Experimental deletion causes abnormal vessel growth, vascular leakage, and altered VEGFR signaling, highlighting CLEC14A’s key role in blood and lymphatic vessel homeostasis and its potential as a therapeutic target in diseases characterized by pathological angiogenesis, such as cancer[1][3][5].

Other names

C14orf27EGFR5UNQ236/PRO269EGFR-5ClECT and EGF-like domain containing proteinCEG1Epidermal growth factor receptor 5

Not directly associated with approved drugs; experimental evidence suggests modulation of angiogenesis via the VEGF/VEGFR pathway (pharmacological inhibition of VEGFR-2 rescues phenotypes caused by CLEC14A deficiency)